Novel metabolites of buprenorphine detected in human liver microsomes and human urine.
The in vitro metabolism of buprenorphine was investigated to explore new metabolic pathways and identify the cytochromes P450 (P450s) responsible for the formation of these metabolites. The resulting metabolites were identified by liquid chromatography-electrospray ionization-tandem mass spectrometry. In addition to norbuprenorphine, two hydroxylated buprenorphine (M1 and M2) and three hydroxylated norbuprenorphine (M3, M4, and M5) metabolites were produced by human liver microsomes (HLMs), with hydroxylation occurring at the tert-butyl group (M1 and M3) and at unspecified site(s) on the ring moieties (M2, M4, and M5). Time course and other data suggest that buprenorphine is N-dealkylated to form norbuprenorphine, followed by hydroxylation to form M3; buprenorphine is hydroxylated to form M1 and M2, followed by N-dealkylation to form M3 and M4 or M5. The involvement of selected P450s was investigated using cDNA-expressed P450s coupled with scaling models, chemical inhibition, monoclonal antibody (MAb) analysis, and correlation studies. The major enzymes involved in buprenorphine elimination and norbuprenorphine and M1 formation were P450s 3A4, 3A5, 3A7, and 2C8, whereas 3A4, 3A5, and 3A7 produced M3 and M5. Based on MAb analysis and chemical inhibition, the contribution of 2C8 was higher in HLMs with higher 2C8 activity, whereas 3A4/5 played a more important role in HLMs with higher 3A4/5 activity. Examination of human urine from subjects taking buprenorphine showed the presence of M1 and M3; most of M1 was conjugated, whereas 60 to 70% of M3 was unconjugated.
Chang
Yan
Y
University of Utah, Center for Human Toxicology, Department of Pharmacology and Toxicology, 417 Wakara Way, Suite 2111, Salt Lake City, UT 84108, USA.
Moody
David E
DE
McCance-Katz
Elinore F
EF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002047:Buprenorphine / Q000737:chemistry / Q000493:pharmacokinetics / Q000652:urine*; D003001:Cloning, Molecular; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007313:Insecta; D050216:Metabolic Detoxication, Phase I; D008862:Microsomes, Liver / Q000378:metabolism*; D015394:Molecular Structure; D009292:Narcotic Antagonists / Q000737:chemistry / Q000493:pharmacokinetics / Q000652:urine*; D011994:Recombinant Proteins / Q000378:metabolism; D021241:Spectrometry, Mass, Electrospray Ionization
D000911:Antibodies, Monoclonal; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D009292:Narcotic Antagonists; D011994:Recombinant Proteins; D002047:Buprenorphine; D003577:Cytochrome P-450 Enzyme System